Tests in bacteria, cells, and mice all came back negative, suggesting the compound does not pose carcinogenic risk through DNA damage mechanisms
They might need specialized dosing protocols to fix their deficiency
This is a workflow argument, not an efficacy argument, and it is the most defensible reason a lab would choose a blend at all
published Phase I safety data in healthy volunteers were reported in conference proceedings, while completed Phase II efficacy results have not appeared in peer-reviewed literature
This makes it a preferred solvent for peptide reconstitution, solution preparation, and experimental consistency in controlled research environments
Diagrammatic Representation: A bidirectional arrow connects the gut and the brain